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ABSTRACT: Ectrodactyly/split hand-foot malformation is genetically heterogeneous with 
more than 100 syndromic associations. Acinar dysplasia is a rare congenital lung lesion of 
unknown etiology which is frequently lethal postnatally. To date, there have been no reports 
of combinations of these two phenotypes. Here we present an infant from a consanguineous 
union with both ectrodactyly and autopsy confirmed acinar dysplasia. SNP array and whole 
exome sequencing analyses of the affected infant identified a novel homozygous Fibroblast 
Growth Factor Receptor 2 (FGFR2) missense mutation (p.R255Q) in the IgIII domain (D3). 
Expression studies of Fgfr2 in development show localization to the affected limbs and 
organs. Molecular modeling, and genetic and functional assays support that this mutation is at 
  
 
This article is protected by copyright. All rights reserved. 
4 
 
least a partial loss-of-function mutation, and contributes to ectrodactyly and acinar dysplasia 
only in homozygosity, unlike previously reported heterozygous activating FGFR2 mutations 
that cause Crouzon, Apert and Pfeiffer syndromes. This is the first report of mutations in a 
human disease with ectrodactyly with pulmonary acinar dysplasia and, as such, homozygous 
loss-of-function FGFR2 mutations represent a unique syndrome. 





Ectrodactyly/split-hand foot malformation (SHFM) can occur as an isolated abnormality but 
is also associated with more than 100 syndromes [Elliott and Evans 2006; Elliott et al., 2005]. 
At least 7 different genetic loci have been mapped [de Mollerat et al., 2003; Elliott and Evans 
2006; Faiyaz-Ul-Haque et al., 2005; Goodman et al., 2002; Ianakiev et al., 2000; Naveed et 
al., 2006; Scherer et al., 1994; Ugur and Tolun 2008]. Acinar dysplasia (Congenital 
Pulmonary Airway Malformation (CPAM) type 0) is a rare perinatal lethal congenital lung 
disease [Chow et al., 2013; Lee 2013]. It is the rarest subtype of CPAM and is characterized 
embryologically by maturational arrest of the lung at the pseudo-glandular stage of 
development [Chow et al., 2013]. Familial cases of acinar dysplasia have been described and 
some reports describe associated congenital abnormalities.  The etiology of acinar dysplasia 
is unknown [Lee 2013]. The combination of acinar dysplasia and ectrodactyly has not been 
described before.   
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Fibroblast growth factor receptor (FGFR2) (OMIM 176943) is a tyrosine kinase receptor and 
is one of four FGF receptors which have roles in the development and homeostasis of various 
tissues and the regulation of metabolism [Goetz and Mohammadi 2013]. When bound by a 
fibroblast growth factor (FGF), FGFR2 monomers dimerize resulting in transphosphorylation 
of tyrosine residues in the phosphotyrosine kinase domain. This activates the kinase activity 
of this receptor leading to the phosphorylation of intracellular targets [Goetz and Mohammadi 
2013]. Fibroblast Receptor substrate 2 alpha (FRS2) (OMIM 607743), a target of FGFR2, lies 
immediately downstream of the receptor and mediates signaling through the MAP Kinase 
pathway [Gotoh et al., 2004; Gotoh et al., 2005]. ERK1/ERK2 (MAPK3/MAPK1, 
respectively), two components of this pathway, become phosphorylated when FGFR2 is 
activated and can traffic to the nucleus where they mediate effects of receptor activation. In 
the nucleus, they phosphorylate relevant targets, thereby promoting cellular proliferation and 
other events [Meister et al., 2013]. The ligand binding extracellular portion of FGFR2 is 
comprised of three immunoglobulin-like domains (D1, D2 and D3) [Goetz and Mohammadi 
2013]. Alternative splicing of the C-terminal portion of the D3 domain determines ligand 
specificity. FGFR2 exists in two major isoforms (IIIb and IIIc), each of which has had the C-
terminal end of the D3 domain encoded by a different exon. IIIb is expressed specifically in 
epithelial cells whilst IIIc is expressed in mesenchymal tissues [Eswarakumar et al., 2005]. 
FGFR2-associated disease is most often due to mutations in the IIIc isoform. Activating 
mutations in FGFR2 cause Crouzon syndrome (OMIM 123500) [Reardon et al., 1994], Apert 
syndrome (OMIM 101200) [Wilkie et al., 1995], Pfeiffer syndrome (OMIM 101600) 
[Muenke et al., 1994; Schell et al., 1995], Jackson-Weiss syndrome (OMIM 123150) [Jabs et 
al., 1994], Beare-Stevenson syndrome (OMIM 123790) [Przylepa et al., 1996], and non-
syndromic craniosynostosis [Carinci et al., 2005; Reardon et al., 1994; Wilkie et al., 2007]. 
The majority of mutations in Crouzon syndrome occur in the D3 domain. Several of these 
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craniosynostosis syndromes have associated limb abnormalities (e.g. broad first finger/toe in 
Pfeiffer syndrome, syndactyly in Apert syndrome), but ectrodactyly is not a general feature of 
these conditions [Garcin et al., 1932] and no primary congenital pulmonary abnormalities 
have been previously described. However, studies in an Fgfr2 mouse model that displays 
Apert syndrome-like phenotypic features showed defects in FGFR2 signaling resulting in 
defective mesenchymal differentiation, inhibition of terminal airway development and 
ultimately an “emphysema like” phenotype throughout the lungs [De Langhe et al., 2006]. 
Here we present a newborn infant of consanguineous parents with a proposed new syndrome 
of lethal acinar dysplasia and ectrodactyly in whom exome sequencing identified a 
homozygous FGFR2 mutation (GRCh37/hg19; Chr10:g.123,279,668C>T; 
NM_000141.4:c.764G>A; NP_000132.3:p.R255Q; FGFR2 IIIc) 
(http://www.lovd.nl/FGFR2). The unique clinical presentation of acinar dysplasia and 
ectrodactyly and the absence of craniosynostosis in the affected infant, her heterozygous 
parents and her sibling, led to our hypothesis that the FGFR2 mutation in this family is at 
least a partial loss-of-function mutation. We performed functional experiments to determine 
the effect of the p.R255Q mutation on the activity of FGFR2 by measuring its effect on 
downstream signaling and to confirm whether FGFR2 is expressed in the tissues involved in 
the phenotype of the affected infant. In silico modeling was also carried out to predict the 
impact of the p.R255Q mutation. This is the first instance of a homozygous FGFR2 missense 
mutation causing disease in humans. 
Materials and Methods 
SNP Array Analysis 
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A SNP array (Illumina HumanCytoSNP-12 v2.1) was performed on the patient's genomic 
DNA from peripheral blood to identify copy number changes and regions of loss of 
heterozygosity due to consanguinity. 
Whole Exome Sequencing (WES) 
Whole exome capture (Agilent Whole Exome SureSelect V4 All Exon Capture Platform; 
Agilent Technologies, Mulgrave, Victoria Australia) and sequencing (Illumina HiSeq2000 
platform; Illumina, Inc, San Diego, CA USA), targeting a total sequence of 51 MB were 
performed at the Australian Genome Research Facility (Parkville, Victoria). Samples were 
sequenced using a paired end 2 x100 sequencing protocol. Reads were mapped to hg19 and 
variants called and annotated as described previously [Gagliardi et al., 2014]. Variants from 
within regions of common descent were screened against dbSNP v135 and Exome 
Aggregation Consortium (ExAC, v0.3.1, http://exac.broadinstitute.org) databases. Filtering 
was carried out on the WES variants under the key assumptions that the disease is completely 
penetrant and that any variants present in the affected infant, which were also present in 
dbSNP v135 with a minor allele frequency (MAF) greater than 0.1%, were non-causative, 
and hence excluded. Homozygous variants within regions of loss of heterozygosity were 
preferentially considered to fit with the predicted autosomal recessive mode of inheritance. 
Variants then underwent SeattleSeq Annotation including Genomic Evolutionary Rate 
Profiling (GERP) [Cooper et al., 2005] and were screened using PolyPhen-2 and Combined 
Annotation Dependent Depletion (CADD, v1.3) [Kircher et al., 2014] to predict 
pathogenicity. Primers were designed to amplify regions containing top hit candidate SNVs 
from patient, parents and an unaffected sibling DNA, and Sanger sequencing was performed 
to confirm their presence and segregation. 
Candidate Gene Expression Using in situ RNA Hybridization 
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The candidate genes were annotated with a locus specific database (Mouse Genome 
Informatics (MGI), Online Mendelian disease database (OMIM) and gene expression 
databases (GenePaint and BioGPS). Whole mount in situ RNA hybridizations were 
performed on the limbs of E11.5 and E12.5 embryonic C57BL/6 inbred mice according to a 
previously published method on the Intavis InsituPro VSi instrument in order to determine 
the expression pattern of FGFR2 during digital development [Riddle et al., 1993]. These 
stages were chosen as development of the digits begins to take place during these times 
[Taher et al., 2011]. RNA in situ probes were designed to target the final exon junction in 
FGFR2 (exon 17-18, 678 bp). The probe sequence was amplified from mouse genomic DNA 
with primers 5’CGAATTCTGACTCTCACAACCA’3 (FOR), 
5’TAGGTGCATCAGGACATCCAT 3’ (REV). Images were taken on a SZX10 stereo 
microscope (Olympus) mounted with a Micropublisher 3.3 digital camera (Q-Imaging). The 
images were processed with OpenLab 2.2 software. 
Generation of FGFR2 WT and Mutant Expression Constructs 
A pRcCMV plasmid expressing the mesenchymal isoform FGFR2 IIIc (NM_000141.4, 
NP_000132.3, transcript variant 1) (pRcCMV-FGFR2) was purchased from OriGene. Using 
site-directed mutagenesis, we generated pRcCMV-FGFR2(p.R255Q) and pRcCMV-
FGFR2(C342Y) (a mutation causing constitutive receptor activation) and pRcCMV-Empty. 
FGFR2 and ERK1/2 Phosphorylation Assays 
Human Embryonic Kidney 293 (HEK293) cells were transfected with FGFR2 WT and 
mutant expression constructs using Lipofectamine 2000 (Life Technologies). The following 
day, after serum starvation, cells were stimulated with fibroblast growth factor 2 (FGF2) at 20 
ng/ml for 5 and 15 min in the presence of 10 µg/ml heparin to promote high affinity FGF2 
binding to FGFR2. Western blots were performed to assess the levels of FGFR2 tyrosine 
phosphorylation and downstream ERK1/2 phosphorylation (p-ERK1/2). Phosphorylation of 
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two tyrosine residues (Y653, Y654) in the activation loop of FGFR2 leads to activation of the 
receptor and downstream signaling [Eswarakumar et al., 2005]. Antibodies used: anti-
phospho ERK1/2 rabbit monoclonal antibody (Cell Signalling Technology, #12638), anti-
ERK1/2 rabbit monoclonal antibody (Cell Signalling Technology, #4695), anti-phospho-
tyrosine monoclonal antibody (Thermo Scientific, MA1-10443) and anti-BEK (C-17) 




The proband was born to healthy first cousin parents of Kurdish heritage; the mother was 20 
years old and the father 23 years old. There was no history of infertility or miscarriages. First-
trimester nuchal translucency and biochemical screening were normal. Ultrasound 
examination at 19 weeks gestation revealed abnormalities of the hands and feet. On the left 
hand the thumb, second, third and fourth fingers were short and the fifth was thought to be 
absent. On the right hand only the index finger was seen. The arm bones appeared to be 
normal on both sides. On both feet, only the first and fifth toe could be identified. In addition 
to the limb abnormalities, there was evidence of echogenicity of the fetal gut. Parental 
hemoglobin electrophoresis and alpha thalassemia genotyping were normal. The couple was 
counselled regarding the differential diagnosis for these abnormalities, declined 
amniocentesis and elected to continue the pregnancy. The female infant was born at 36 weeks 
gestation following spontaneous onset of labour. Birthweight was 2.3 kg (15
th
 percentile). 




) and required immediate ventilatory 
support for severe respiratory distress. Chest x-ray was consistent with severe pulmonary 
hypoplasia and ventilatory support was withdrawn at 5 hours of age; the infant died shortly 
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after. Dysmorphic facial features were noted with epicanthic folds, a small mouth (23 mm, 
normal range 26 ± 2.5 mm), mild hypertelorism (78 mm, normal range 65 ± 3.5 mm), a broad 
nasal bridge and bulbous nasal tip, low set ears and obvious narrowing of the external 
auditory canals bilaterally which remained patent (Figure 1A and B). The fontanelles were 
normal and there were no features to suggest craniosynostosis. Both parents had normal 
physical examinations. X-ray of the mother’s skull showed no abnormalities (Supp. Figure 
S1). 
There were 4 digits on the left hand and a cleft extending into the palm between fingers 2 and 
3 (Figure 1C, D and H). There was skin syndactyly between fingers 1 and 2, and fingers 3 
and 4. Fingers 1-3 were considerably shorter than the fourth finger. There was no 
recognizable thumb. Only one digit was recognizable on the right hand and this digit was 
attached to a broad base (Figure 1E and 1J). There were 4 digits identifiable on the right foot 
with the appearance of a bifid first toe and a cleft extending into the dorsum of the right foot 
between the bifid first/second toe and toes 4 and 5 (Figure 1F). There were 4 recognizable 
digits on the left foot including a large first toe (not shown). There was syndactyly between 
the second and third toes on this foot and a cleft between the first and second toes. These 
limb abnormalities were thought to represent a severe form of ectrodactyly with both 
oligodactyly and syndactyly. X-rays of the hands (Figure 1G corresponding to Figure 1H, and 
Figure 1I corresponding to Figure 1J) and feet performed at autopsy confirmed a 
disorganized pattern with absent or short phalanges, variable degrees of syndactyly, 
ectrodactyly, oligodactyly and bifid bones. Skeletal radiological survey was otherwise normal 
with no abnormalities of the cranial vault. The lungs were small at autopsy (combined weight 
26.89 g; normal for 36 week female 36.7± 16.8 g) and had abnormal lobation with 2 lobes on 
the right and one on the left (Figure 1K). Histological examination demonstrated severe 
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maturational arrest of lung tissue at the pseudoglandular stage and multiple small cysts of 
<0.5 cm in diameter consistent with a diagnosis of acinar dysplasia (Figure 1L and 1M). 
SNP Array and Whole Exome Sequencing to Identify Causal Candidate Gene 
Mutations 
No significant copy number changes were identified in the genome of the affected infant 
using SNP array. There were however long continuous stretches of homozygosity 
representing approximately 6% of the genome, consistent with the degree of consanguinity 
expected for offspring of first cousins. 
Whole exome sequencing (WES) was then performed on the affected infant, and following 
removal of variants present at a MAF>0.1% in dbSNP v135, coding variants were identified 
in 21 genes within the regions of loss of heterozygosity (LOH). These were further filtered to 
remove unlikely pathogenic variants with PolyPhen2 (benign), GERP (<2) and CADD (<10) 
using SeattleSeq Annotation which further narrowed down the number to 13 candidate 
variants. Analysis of gene expression patterns matching sites of developmental perturbations 
in the infant with The e-Mouse Atlas Project and Mouse Genome Informatics resulted in 5 
genes; FGFR2, GGA3, COL12A1, UBE2Q2 and SPATA13. Segregation analysis of the 5 
variants on both parents, the affected infant and her sibling using Sanger sequencing was 
consistent with autosomal recessive inheritance of the disease for all variants except for 
SPATA13 which was homozygous in the unaffected sibling and hence was excluded. 
Of the 4 remaining genes, the mutation in FGFR2 (p.R255Q; Table 1) was considered to be 
the most likely causative gene based on Online Mendelian Inheritance in Man (OMIM) 
phenotypes, expression data (BioGPS), a FGFR2 mouse model [Mai et al., 2010], in silico 
modeling, and functional studies (outlined below). Sanger sequencing of each family member 
for segregation of FGFR2 (p.R255Q) is shown in Figure 2A and B. Variants in GGA3, 
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COL12A1 and UBE2Q2 were excluded as candidates due to clinical, phenotypic and/or 
expression inconsistencies when compared to the affected individual (Table 1). 
FGFR2 Expression Marks Tissues Affected in this Patient 
To more clearly define the expression profile of FGFR2 in developing limbs and lungs, we 
performed in situ RNA hybridization on a staged series of mouse embryos. FGFR2 
expression was seen in the developing limbs at day E11.5 and E12.5. At E11.5, there was 
strong expression in the hindlimbs and forelimbs, specifically in mesenchymal condensations 
that will later give rise to bone (Figure 3A). By E12.5, FGFR2 expression was localized to 
the webbing between the developing digits in the forelimbs and hindlimbs, tissues consistent 
with the aberrant development seen in the patient. Expression was also seen in the developing 
epithelium of E14.5 lungs which is consistent with the defects associated with acinar 
dysplasia (Figure 3B). 
An Important Role for R255 in the Protein – in silico Modeling 
The wildtype R255 amino acid residue in FGFR2 and its surrounding sequence is highly 
conserved across multiple species including chimpanzee, mouse, chicken and zebrafish, and 
in all human FGFR family members (Figure 4A and Supp. Figure S2). The p.R255Q variant 
is situated at the D3 domain end of the linker between domains D2 and D3 (Figure 4B), and 
within a hotspot of germline mutations that cause Crouzon and Apert syndromes and non-
syndromic craniosynostosis (Figure 4C). R255 with H254 and I348 forms a pocket for the 
binding of a sulfate ion from heparan sulphate (Figure 4D, top), [Golovin et al., 2005; 
Stauber et al., 2000] a glycoprotein that facilitates high affinity binding of the FGF ligand to 
the FGFR2 receptor [Plotnikov et al., 2000] which is a necessary for active signaling from the 
cytoplasmic receptor tyrosine kinase [Stauber et al., 2000]. The p.R255Q mutation likely 
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prevents binding of this sulfate ion, which may impact on receptor activation and downstream 
signaling (Figure 4D, bottom).  
FGFR2 (p.R255Q) Displays Loss-Of-Function Properties 
To ascertain the functional effect of the p.R255Q mutation on FGFR2 signaling, we 
measured phosphorylation of FGFR2 and its downstream effectors ERK1/2 in response to the 
activating ligand FGF2. Phosphorylation of 2 tyrosine residues (Y653 and Y654) in the 
activation loop of FGFR2 leads to activation and signaling of the receptor [Eswarakumar et 
al., 2005]. As a positive control, we included a known Crouzon syndrome mutation C342Y, 
which causes homodimerization and constitutive activation of FGFR2 resulting in increased 
basal ERK1/2 phosphorylation [Krejci et al., 2012]. Human Embryonic Kidney 293 
(HEK293) cells were transiently transfected with constructs to express FGFR2 WT and 
mutants. Following a period of serum starvation, the cells were stimulated with FGF2 for 5 
and 15 min. FGFR2 (p.R255Q) mutant displayed similar basal receptor phosphorylation as 
WT, but in response to FGF2, did not achieve the same level of increased FGFR2 
phosphorylation, which is seen more notably in downstream ERK1/2 phosphorylation, as did 
WT (Figure 5 and Supp. Figure S3). For FGFR2 phosphorylation, 4 individual blots are 
shown as they were difficult to quantify due to the large size of the protein and spread of the 
bands. C342Y showed high basal FGFR2 phosphorylation and heightened basal and FGF2-
stimulated ERK1/2 activation consistent with a constitutively active mutant. Overall, 
p.R255Q demonstrates properties of at least a partial loss-of-function mutation consistent 
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This case of a unique phenotype of ectrodactyly and acinar dysplasia represents the first 
human case of homozygous FGFR2 disease to the best of our knowledge. RNA in situ 
hybridization data revealed expression in the affected tissues in mice (forelimbs, hindlimbs 
and the lung) and protein alignments revealed a high level of conservation for the R255 
residue. Fgfr2 knockout mice show complete absence of limb outgrowth and defects in lung 
branching morphogenesis [Arman et al., 1999]. Further, a homozygous knock-in mouse 
model of a gain-of-function Fgfr2
W290R
 mutant developed by others overlaps most of the 
abnormalities observed in our patient [Mai et al., 2010]. Interestingly however, while 
Fgfr2
W290R/+
 mice have normal limb development consistent with Crouzon syndrome, 
Fgfr2
W290R/W290R 
developed major reductive limb abnormalities and small lungs and died on 
the first day of life. It is clear that the lungs in this mouse model are markedly small and 
underdeveloped [Mai et al., 2010]. The Fgfr2
W290R/W290R 
mice also displayed abnormalities of 
the cranial vault, although no craniosynostosis was seen consistent with observations for our 
infant with homozygous FGFR2
R255Q/R255Q
 mutation. The overall analysis of FGFR2 gain-of-
function and loss-of-function mouse models suggest that various organs respond differently 
to heterozygous and homozygous mutant genotypes. Further, in some tissues, perturbation of 
FGFR2 signaling, either up or down, results in the same phenotype while in other tissues 
produces opposite effects (summarized in Mai et al., [2010]). The predominantly distal 
pattern of limb abnormalities in our case may suggest more complex involvement of FGFR2 
in human limb development or result from this at least partial loss-of-function mutation. 
Consistent with loss-of-function of FGFR2 in our patient causing lung and limb abnormalities 
is phenotypic data from a mouse model of homozygous loss-of-function mutation in FGF10, 
an endogenous ligand of FGFR2 [Sekine et al., 1999]. In this study, homozygous FGF10-
deficient mice died at birth due to lack of lung development. Severe pulmonary branching 
morphology was disrupted. Mutant mice also had complete truncation of the fore- and 
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hindlimbs [Sekine et al., 1999]. Based on genetic inheritance pattern, functional studies, and 
our patient and parental phenotypes, we propose that the homozygous FGFR2 mutation is 
most likely a loss-of-function. FGF2 stimulation assays showed that this mutation displays 
decreased but not completely abrogated activation and signaling in downstream pathways, 
providing evidence of at least partial loss-of-function. Furthermore, segregation analysis 
supports the candidacy of this gene and in situ RNA hybridization in mice point to the 
involvement of this gene in limb and lung development. Further functional work will be 
required to confirm the exact mechanism by which this gene mutation leads to loss-of-
function of FGFR2. 
Gain-of-function mutations in FGFR2 have consistently caused craniosynostosis syndromes 
[Hatch et al., 2006]. These gain-of-function mutations in craniosynostosis syndromes are 
thought to do so through receptor activation and some are glycosylation-dependent [Hatch et 
al., 2006]. In our study, we provide evidence that the FGFR2 p.R255Q mutation is at least 
partial loss-of-function. Neither parent has evidence of craniosynostosis on physical 
examination; the mother has had a skull x-ray with no evidence of craniosynostosis and both 
the father and the heterozygous sibling have no evidence of craniosynostosis. Similarly, 
dominant activating mutations in FGFR3 cause a variety of short-limbed bone dysplasias 
including achondroplasia and syndromic craniosynostosis. But recently, WES identified a 
homozygous loss-of-function mutation in FGFR3 in humans characterized by tall stature and 
severe skeletal abnormalities leading to inability to walk, with camptodactyly, 
arachnodactyly, and scoliosis [Makrythanasis et al., 2014]. 
Somatic loss-of-function mutations in FGFR2 are associated with malignant melanoma, but 
no previous cases of germline FGFR2 loss-of-function mutations have been described 
[Gartside et al., 2009]. The combination of acinar dysplasia with ectrodactyly has not been 
previously reported although there is one report of ectrodactyly and capillary alveolar 
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dysplasia, another lethal lung disease, in association with tibial agenesis [Witters et al., 2001]. 
Three children in one consanguineous family were affected, suggestive of autosomal 
recessive inheritance. The first infant died in the neonatal period of pulmonary hypertension, 
secondary to congenital alveolar capillary dysplasia and had tibial agenesis and ectrodactyly. 
The second infant had similarly severely affected lungs but normal limbs. A third affected 
pregnancy occurred with bilateral agenesis of the tibia, symmetric ectrodactyly of the hands 
and feet and alveolar capillary dysplasia. The genetic cause of these familial abnormalities 
has not been identified (personal communication with Witters). Isolated alveolar capillary 
dysplasia with misalignment of pulmonary veins (ACDMPV; OMIM 265380) is caused by 
heterozygous mutations in FOXF1 (OMIM 601089) or its regulatory region and follows an 
autosomal dominant mode of inheritance [Sen et al., 2013]. FOXF1 is expressed in 
developing capillaries rather than developing epithelium. It is interesting that germline 
mutations in Crouzon syndrome and somatic mutations in endometrial cancer have been 
shown to be gain-of-function while somatic mutations in melanoma are loss-of-function 
[Gartside et al., 2009]. For these three conditions, there are no mutations in common although 
they are somewhat scattered linearly along the primary protein sequence. Hence, for any 
newly identified variant, it may be very difficult to predict its phenotypic impact without 
functional testing. 
Here we report a novel germline FGFR2 mutation which displays yet another phenotype, and 
which is flanked immediately by Crouzon syndrome mutations. In our unique case, we have 
identified a homozygous at least partial loss-of-function mutation in FGFR2 associated with a 
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Figure 1.  Anatomical and histological features of affected infant. A and B: Head and face, C 
and D: left hand, and E: right hand. X-rays of G and H: left hand and I and J: right hand. 
Acinar dysplasia of affected infant’s autopsy lung at 36 weeks gestation. K: Photograph of 
heart and lungs showing greatly reduced lung size. Hematoxylin and Eosin staining of L: 
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Figure 2.  Pedigree of infant affected with ectrodactyly and acinar dysplasia and segregation 
analysis of FGFR2 (p.R255Q) mutation. A: Pedigree of affected family showing FGFR2 
genotype. B: Sanger sequencing of FGFR2 mutation in affected family confirms parental 

















Figure 3.  FGFR2 in situ RNA hybridization of embryonic mouse. A: Whole mount in situ of 
mouse embryo limbs at embryonic day 11.5 and 12.5. B: Sagittal section of in situ RNA 
hybridization of embryonic mouse E14.5 (Image from genepaint.org, image set ID:FG35, 
Image 5D). 
 
Figure 4.  Conservation of FGFR2 R255 across species and structural modeling to show its 
function. A: Conservation of amino acid R255 in FGFR2 across species. Multiple Alignment 
in HomoloGene (NCBI) was used to align the orthologous amino acid residues to human 
R255 and surrounding sequence in the species shown. Extracellular immunoglobulin-like 
domains D2 and D3 are shown below alignments. B: Position of known FGFR2 disease-
causing mutations and R255Q. R255Q (orange) is located in the D3 Ig-like domain of 
FGFR2 near the ligand binding surface. Previously identified activating mutations from 
HGMD® Human Gene Mutation Database (BIOBASE) (green) are predominantly located 
throughout the D3 domain. C: Position of R225Q in the FGFR2 protein in relation to other 
disease-causing activating mutations. Shown is FGFR2 (NM_000141.4, variant 1; 
NP_000132.3, isoform IIIc) with immunoglobulin-like domains (D1-3, bind FGF ligands), 
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acidic box (AB, binds bivalent cations for optimal interaction with heparin sulfate 
proteoglycans), transmembrane domain (TM) and tyrosine kinase domain (kinase). Crouzon 
(orange), Pfeiffer (purple) and Apert (green) syndromes, non-syndromic craniosynostosis and 
others (blue). Mutations were obtained from Human Gene Mutation Database (HGMD). D: 
Effect of p.R255Q on FGFR2 binding to its ligand. Molecular structure of human FGF1 
ligand (pale yellow) to wild-type (WT) human FGFR2 (D3 in deep blue and D2 in light 
blue). Negatively charged sulphate ions (green) from ligand-associated heparin sulphate are 
able to associate with the WT R255 (orange) and adjacent residues H254 (pink) and I348 
(magenta). R255Q leads to the replacement of a large, positive side chain with a smaller 
neutral one, which may negatively impact binding of heparin sulphate to the receptor, leading 
to a loss of receptor activation. The loss of this charged chain is also predicted to alter the 
confirmation of the D3 Ig-like domain which may further inhibit activation. The WT crystal 
structure (PDB ID: 1DJS) is from Stauber et al. [Stauber et al., 2000]. Visualization is via 
PyMOL (Version 1.5.0.3 Schrödinger, LLC). 
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Figure 5.  FGFR2 and ERK1/2 activation studies to determine effect of p.R255Q on FGFR2 
function. HEK293 cells were transfected with FGFR2 WT or mutant constructs. After 20 h, 
the cells were serum starved for 4 h and then 20 ng/ml FGF2 with 10 µg/ml heparin was 
added. A: Cells were harvested after 0, 5 and 15 min, lysates run on western blots, and blots 
probed with anti-phospho ERK1/2, anti-ERK1/2, anti-phospho-tyrosine and anti-FGFR2 
antibodies. B: Bar graph showing the densitometric quantification of FGFR2 phosphorylation 
levels from a representative western blot. C: ERK1/2 phosphorylation levels were quantified 
and standardized to unphosphorylated protein. Protein band intensities across blots were 
normalized to the standardized p-ERK value for FGFR2 WT at time 0 (set to 1). The graph 
shows the mean ± S.E.M. of 4 independent experiments. Statistical analysis was performed 
using Mann-Whitney test.  
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Variants where identified by whole exome sequencing. These 4 candidate variants are 
changes in highly conserved amino acids, are in conserved regions across species, and are 
predicted to negatively impact protein function. Asterisk, UBE2Q2 (dupGT) is predicted by 
splice predictor programs Alternative Splice Site Predictor and Alamut 2.0 Splicing 
Prediction Module to potentially cause a 2 nt frameshift. Autosomal dominant, AD; 
Autosomal recessive, AR. Expression was determined using BioGPS, MGI and GenePaint. 
For cDNA numbering, nucleotide numbering uses +1 as the A of the ATG translation 
initiation codon in the reference sequence, with the initiation codon as codon 1. 
 
 
 
 
 
 
 
